论文部分内容阅读
美国国立癌症研究所于1988年8月10日首次用合成CD4受体治疗AIDS。试验使用旧金山基因技术公司通过哺乳动物细胞生产的重组蛋白制品,受试人包括50名AIDS患者或有AIDS相关的复合体征(ARC)但未接受AZT(azidothymindine,叠氮胸苷)治疗的患者。ARC患者将出现细胞计数低的症状。旧金山综合医院和新英格兰迪肯尼斯医院也将参加这项试验。因为CD4受体是AIDS病毒最初在T4辅助细胞上结合而进入细胞内的部位,合成的受体可能与T4辅助细胞竞争病毒。如果合成受体竞
The National Cancer Institute first used AIDS-causing CD4 receptor on August 10, 1988. The trial used recombinant protein preparations produced by mammalian cells from San Francisco Gene Technology Inc. The subjects included 50 AIDS patients or patients with AIDS-related complex signs (ARC) who did not receive AZT (azidothymidine). Patients with ARC will have low cell count symptoms. San Francisco General Hospital and New England Di Kenneth Hospital will also participate in the trial. Because the CD4 receptor is the site of the AIDS virus that initially enters the cell on T4 helper cells, the synthetic receptor may compete with T4 helper cells for viruses. If synthetic receptor competition